The computational prediction of genotoxicity
暂无分享,去创建一个
[1] Lutz Müller,et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. , 2006, Regulatory toxicology and pharmacology : RTP.
[2] Carol A Marchant,et al. In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.
[3] Naomi L. Kruhlak,et al. In Silico Screening of Chemicals for Genetic Toxicity Using MDL-QSAR, Nonparametric Discriminant Analysis, E-State, Connectivity, and Molecular Property Descriptors , 2008, Toxicology mechanisms and methods.
[4] Naomi L Kruhlak,et al. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products. , 2007, Advanced drug delivery reviews.
[5] Lutz Müller,et al. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. , 2005, Mutation research.
[6] Ronald D Snyder,et al. DNA intercalative potential of marketed drugs testing positive in in vitro cytogenetics assays. , 2006, Mutation research.
[7] Ronald D Snyder,et al. Assessment of atypical DNA intercalating agents in biological and in silico systems. , 2007, Mutation research.
[8] Ernesto Estrada,et al. Automatic extraction of structural alerts for predicting chromosome aberrations of organic compounds. , 2006, Journal of molecular graphics & modelling.
[9] Warren E Glaab,et al. A low volume, high-throughput forward mutation assay in Salmonella typhimurium based on fluorouracil resistance. , 2005, Mutation research.
[10] Stephanie Ringeissen,et al. Evaluation of ( Q ) SAR models for the prediction of mutagenicity potential , 2006 .
[11] Stephen R. Johnson,et al. The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy) , 2008, J. Chem. Inf. Model..
[12] M Natália D S Cordeiro,et al. A topological substructural molecular design approach for predicting mutagenesis end-points of alpha, beta-unsaturated carbonyl compounds. , 2010, Toxicology.
[13] Klaus-Robert Müller,et al. Benchmark Data Set for in Silico Prediction of Ames Mutagenicity , 2009, J. Chem. Inf. Model..
[14] P. Jurs,et al. Development of binary classification of structural chromosome aberrations for a diverse set of organic compounds from molecular structure. , 2003, Chemical research in toxicology.
[15] Maykel Pérez González,et al. Halogenated derivatives QSAR model using spectral moments to predict haloacetic acids (HAA) mutagenicity. , 2008, Bioorganic & medicinal chemistry.
[16] Jiri Aubrecht,et al. Bioluminescent Salmonella reverse mutation assay: a screen for detecting mutagenicity with high throughput attributes. , 2007, Mutagenesis.
[17] Romualdo Benigni,et al. Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology. , 2008, Mutation research.
[18] Ovanes Mekenyan,et al. Identifying the structural requirements for chromosomal aberration by incorporating molecular flexibility and metabolic activation of chemicals. , 2007, Chemical research in toxicology.
[19] Mark Whittaker,et al. An in Silico Method for Predicting Ames Activities of Primary Aromatic Amines by Calculating the Stabilities of Nitrenium Ions , 2010, J. Chem. Inf. Model..
[20] Shane Weaver,et al. The importance of the domain of applicability in QSAR modeling. , 2008, Journal of molecular graphics & modelling.
[21] R Scott Obach,et al. A strategy for the risk assessment of human genotoxic metabolites. , 2009, Chemical research in toxicology.
[22] R Serafimova,et al. Identification of the structural requirements for mutagencitiy, by incorporating molecular flexibility and metabolic activation of chemicals. II. General Ames mutagenicity model. , 2007, Chemical research in toxicology.
[23] Naomi L Kruhlak,et al. A structural feature-based computational approach for toxicology predictions , 2010, Expert opinion on drug metabolism & toxicology.
[24] Andrew Worth,et al. Structural analysis and predictive value of the rodent in vivo micronucleus assay results. , 2010, Mutagenesis.
[25] Qing-You Zhang,et al. Random Forest Prediction of Mutagenicity from Empirical Physicochemical Descriptors , 2007, J. Chem. Inf. Model..
[26] Melvin E Andersen,et al. Toxicity Testing in the 21st Century: Implications for Human Health Risk Assessment , 2009, Risk analysis : an official publication of the Society for Risk Analysis.
[27] Paolo Mazzatorta,et al. Integration of Structure-Activity Relationship and Artificial Intelligence Systems To Improve in Silico Prediction of Ames Test Mutagenicity , 2007, J. Chem. Inf. Model..
[28] R. Snyder,et al. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules , 2004, Environmental and molecular mutagenesis.
[29] David Kirkland,et al. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. , 2005, Mutation research.
[30] Jan G Hengstler,et al. Carcinogenicity categorization of chemicals-new aspects to be considered in a European perspective. , 2004, Toxicology letters.
[31] P Gramatica,et al. Prediction of PAH mutagenicity in human cells by QSAR classification , 2008, SAR and QSAR in environmental research.
[32] Robert J Kavlock,et al. Computational toxicology--a state of the science mini review. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[33] Romualdo Benigni,et al. Predictivity of QSAR , 2008, J. Chem. Inf. Model..
[34] Pramod C. Nair,et al. Comparative QSTR studies for predicting mutagenicity of nitro compounds. , 2008, Journal of molecular graphics & modelling.
[35] Yvonne Connolly Martin. What Works and What Does Not: Lessons from Experience in a Pharmaceutical Company , 2007 .
[36] Christoph Helma,et al. Lazy structure-activity relationships (lazar) for the prediction of rodent carcinogenicity and Salmonella mutagenicity , 2006, Molecular Diversity.
[37] Gilles Marcou,et al. Predicting the Predictability: A Unified Approach to the Applicability Domain Problem of QSAR Models , 2009, J. Chem. Inf. Model..
[38] Luis G Valerio,et al. In silico toxicology for the pharmaceutical sciences. , 2009, Toxicology and applied pharmacology.
[39] Naomi L Kruhlak,et al. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. , 2007, Regulatory toxicology and pharmacology : RTP.
[40] G M Pearl,et al. Integration of computational analysis as a sentinel tool in toxicological assessments. , 2001, Current topics in medicinal chemistry.
[41] Hans Bitter,et al. Identification of a Kinase Profile that Predicts Chromosome Damage Induced by Small Molecule Kinase Inhibitors , 2009, PLoS Comput. Biol..
[42] N. Kruhlak,et al. An analysis of genetic toxicity, reproductive and developmental toxicity, and carcinogenicity data: II. Identification of genotoxicants, reprotoxicants, and carcinogens using in silico methods. , 2006, Regulatory toxicology and pharmacology : RTP.
[43] Romualdo Benigni,et al. Predictivity and Reliability of QSAR Models: The Case of Mutagens and Carcinogens , 2008, Toxicology mechanisms and methods.
[44] J. Kazius,et al. Derivation and validation of toxicophores for mutagenicity prediction. , 2005, Journal of medicinal chemistry.
[45] P. Kovacic,et al. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress? , 2003, Current medicinal chemistry.
[46] R Benigni,et al. Understanding Genetic Toxicity Through Data Mining: The Process of Building Knowledge by Integrating Multiple Genetic Toxicity Databases , 2008, Toxicology mechanisms and methods.
[47] Maxime Robin,et al. DNA-damaging activity and mutagenicity of 16 newly synthesized thiazolo[5,4-a]acridine derivatives with high photo-inducible cytotoxicity. , 2008, Mutation research.
[48] R Scott Obach,et al. Strategy for genotoxicity testing--metabolic considerations. , 2007, Mutation research.
[49] Wolfgang Muster,et al. Computational toxicology in drug development. , 2008, Drug discovery today.
[50] R. Tennant,et al. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP. , 1991, Mutation research.
[51] Ronald D Snyder,et al. An update on the genotoxicity and carcinogenicity of marketed pharmaceuticals with reference to in silico predictivity , 2009, Environmental and molecular mutagenesis.
[52] Nigel Greene,et al. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. , 2006, Regulatory toxicology and pharmacology : RTP.
[53] N Flamand,et al. Mini mutagenicity test: a miniaturized version of the Ames test used in a prescreening assay for point mutagenesis assessment. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.